Climb Bio, Inc. (CLYM)
Climb Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wellesley Hills, MA, US. The stock last traded at $14.26, up 2.94% on the session, giving a market capitalisation of $816.4M. On trailing twelve-month figures it carries a trailing P/E of -17.18, a net margin of 0.0%. Its beta of 0.07 implies it has historically moved less than the broad market.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Climb Bio, Inc. is most often compared with the following Healthcare names: